Clinical Trials & Research

21216 - Ph2 Trila Avel Uro Carcinoma

A Phase 2, Randomized, Open-Label Study of Trilaciclib Administered with First-Line Platinum-Based Chemotherapy and Avelumab Maintenance Therapy in Patients with Untreated, Locally Advanced or Metastatic Urothelial Carcinoma (PRESERVE 3)(G1T28-209)

Disease Types: Bladder,&nbs

Available at: {clinical_trial_location backspace="7"} 21216 - Ph2 Trila Avel Uro Carcinoma, {/clinical_trial_location}

Principal Investigator: {clinical_trial_principle_investi} , {/clinical_trial_principle_investi}

{clinical_trial_description}